American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

American Head & Neck Society | AHNS


The mission of the AHNS is to advance Education, Research, and Quality of Care for the head and neck oncology patient.

  • About
    • Mission Statement and Purpose
    • Divisions & Services of the Society
      • Education
        • Scientific Program/Resident Courses
        • Surgical Videos
        • Journal Club
        • Journals
        • Global Outreach
        • Awards
          • Margaret F. Butler Award
      • Diversity, Equity and Inclusion Division
      • Patient Care
        • Cancer Survivorship
          • Patient Education on Post-Treatment Care
          • Interviews with Cancer Survivors
        • Cancer Prevention
          • SLIDE DECK: HPV-Related Oropharyngeal Cancer
        • Guidelines/Position Statements
        • Find-A-Physician
      • Research
        • Grant Information
        • Clinical Trial
        • Tissue Banks
      • Administrative Divison
        • Development Service Process for Evaluating Projects Requiring Funding
    • Leadership
    • History
      • Society Background
      • AHNS History Interviews
      • Past Presidents
      • In Memory
    • AHNS Newsletter
    • Professionalism & Ethics
    • AHNS Policies and Procedures (P&P) Manual
    • AHNS Foundation
    • AHNS Bylaws
    • AHNS Staff
    • AHNS News and Announcements
    • COVID-19 Bulletin Board
  • Heads Up!
  • Post a Job
  • Meetings
    • AHNS Virtual Education Series
      • TORS Webinar Series
    • AHNS Meetings Info
    • AHNS Call For Abstracts
    • AHNS Call For Late Breaking Abstracts
    • Exhibitor and Support Opportunities
    • Past Meetings
    • Related Meetings
  • For Patients
  • For Trainees
    • Accredited Fellowships
      • Fellowship Match
      • Directory of Fellowships
      • Fellowship Curriculum
      • Certificate of Completion Request
      • Fellowship Graduates
      • For Program Directors
      • For Current AHNS Fellows
    • AHNS Surgical Videos
    • Fellows’ Virtual Tumor Boards
    • Cutaneous Cancer
  • Sections
    • Endocrine Surgery
    • Skull Base Surgery Section
    • Reconstructive Head & Neck Surgery
    • Mucosal Malignancy Section
      • Mucosal Malignancy Section Patient Information
    • Salivary Gland
    • Cutaneous Cancer
  • Member Central
    • Join AHNS
    • Find-A-Physician
    • Mailing List Order
  • Log In
  • Donate

Published on February 8, 2021 by Aviram Mizrachi

Cutaneous Malignancies in the Organ Transplant Population

Case

A 68 y/o man with a history of kidney transplantation on Tacrolimus and prednisone treatment.

Several months prior to his presentation he underwent excision of a Rt temple skin lesion by a plastic surgeon. Pathology revealed a 4 mm SCC with evidence of PNI and free surgical margins. No further treatment or follow-up was recommended.

The patient presents now after noticing a weakness of Rt eyebrow for the last two months. He was seen at the Ophthalmology clinic and diagnosed with complete paralysis of the Rt temporal branch of CN-VII. In addition, there was a 2 cm firm subcutaneous painless mass on the Rt temple, deep to the surgical scar. Biopsy of the Rt temple lesion showed SCC. The patient was then referred to the head and neck clinic for further evaluation and treatment. There were no additional findings on physical examination and imaging studies did not show evidence of regional or distant disease (Figures 1, 2).

Figure 1
Figure 2: PET-CT

 

 

 

 

 

 

Risk of recurrence or metastases

The above case depicts a patient with a high risk for disease recurrence and/or metastases due to chronic immunosuppression. A recent review summarizes the role of the immune system in cutaneous SCC (Figure 3). In this paper the authors illustrate the effect of immunosuppressive drugs on several carcinogenic mechanisms including DNA repair, synergism with UV-related DNA damage, angiogenesis and invasiveness.  The NCCN guidelines address the group of high-risk patients with skin SCC and specify the risk factors that warrant close follow-up. Pay attention to “Area H” that includes the “Mask areas” of the face and is considered a high-risk feature (Figure 4).

Management

Every attempt should be made to achieve complete excision of the primary lesion with negative margins. Modification or reduction of immunosuppression should be considered and consulting the appropriate discipline (nephrologist, hepatologist etc.) is strongly encouraged. Adjuvant radiation may be recommended in cases of perineural involvement of large nerves. However, it should be noted that the definition of large nerves by AJCC 8th edition for skin SCC of the head and neck is above 0.1 mm and most nerves deep to the dermis are above 0.1 mm. Moreover, the survival benefit of adjuvant radiation following complete resection of the primary lesion remains unclear (Figure 5).

Outcomes

Several studies addressed the differences in survival outcomes between immunosuppressed and immunocompetent patients with skin SCC. A recent multi-center study reported on 67 immunosuppressed patients, most of them solid organ recipients, and compared them with 138 immunocompetent patients (Figure 8). They found better progression free survival and locoregional control in the immunocompetent patients group. However, no difference in overall survival between the two groups was noted. Another study by Ritter et al. compared 177 solid organ recipients with 177 immunocompetent patients with skin SCC. They found a significantly higher recurrence rate and worse overall survival in the solid organ recipients group (Figure 6).

Checkpoint inhibitors 

Immunocompromised patients have been traditionally excluded from the major clinical trials on checkpoint inhibitors. Solid organ recipients and patients with chronic viral infections (HIV, HBV, HCV) are considered poor candidates for checkpoint inhibitors due to the risk of allograft rejection and disease flare-up respectively. A multi-center European study reported on 46 patients treated with anti-PD-1/PD-L1 agents. Of them 6 were solid organ recipients and the remaining had chronic viral infections. They concluded that while patients with chronic viral infection may be safely treated with anti-PD-1/PD-L1 drugs, in solid organ recipients the risk of allograft rejection needs to be carefully weighed against the benefit of immunotherapy (Figure 7).

 

“CONCLUSION: Patients with HIV or hepatitus B/C infection treated with anti-PD-1/PD-L1 immunotherapy may respond to treatment without increased toxicity. Given the risk of graft rejection in solid organ transplant patients and also the potential for response, the role of anti-PD-1/PD-L1 immunotherapy needs to be carefully considered.”

 

Another study from MD Anderson Cancer Center reported on 37 solid organ recipients treated with checkpoint inhibitors. They found that 41% of patients experienced allograft rejection with a median time to rejection of 21 days from the initiation of immunotherapy. Furthermore, patients with allograft rejection had a significantly worse overall survival (Figure 8).

There is certainly a need for prospective trials in order to optimize the use of checkpoint inhibitors in immunosuppressed patients. A recently opened trial is enrolling kidney transplant recipients with advanced cancers, with an aim to treat them with Tacrolimus, Nivolumab and Ipilimumab. Additional details on this topic and the trial can be found in the following link:

https://ascopost.com/issues/march-10-2020/immune-checkpoint-inhibitors-in-solid-organ-transplant-recipients/

References

  • Bottomley MJ, Thomson J, Harwood C, Leigh I. The Role of the Immune System in Cutaneous Squamous Cell Carcinoma. Int J Mol Sci. 2019 Apr 24;20(8):2009. doi: 10.3390/ijms20082009. PMID: 31022866; PMCID: PMC6515307.
  • National Comprehensive Cancer Network. Squamous Cell Skin Cancer (Version 2.2020). https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf
  • Manyam BV, Garsa AA, Chin RI, Reddy CA, Gastman B, Thorstad W, Yom SS, Nussenbaum B, Wang SJ, Vidimos AT, Koyfman SA. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer. 2017 Jun 1;123(11):2054-2060. doi: 10.1002/cncr.30601. Epub 2017 Feb 7. PMID: 28171708.
  • Ritter A, Badir S, Mansour M, Segal Z, Ad-El D, Bachar G, Shpitzer T, Popovtzer A, Mizrachi A. Solid organ transplantation worsens the prognosis of patients with cutaneous squamous cell carcinoma of the head and neck region-Comparison between solid organ transplant recipients and immunocompetent patients. Head Neck. 2020 Nov 27. doi: 10.1002/hed.26546. Epub ahead of print. PMID: 33247523.
  • Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20. PMID: 30347289.
  • Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019 Apr 16;7(1):106. doi: 10.1186/s40425-019-0585-1. Erratum in: J Immunother Cancer. 2019 Jun 24;7(1):158. PMID: 30992053; PMCID: PMC6469201.
  • Bio
  • Latest Posts
Aviram Mizrachi

Aviram Mizrachi

Dr. Aviram Mizrachi is a surgeon-scientist at the Department of Otolaryngology – Head and Neck Surgery of Rabin Medical Center in Israel. He has an active research laboratory focusing on tumor and radiation biology in head and neck cancer as well as targeted drug delivery. Furthermore, he investigates both radiation and chemotherapy mechanisms of action and their effect on tumor and normal tissue including the utility of novel radio-sensitizing and radio-protective agents. In addition, Dr. Mizrachi conducts clinical research on outcomes in head and neck, skin and thyroid cancers.
Aviram Mizrachi

Latest posts by Aviram Mizrachi (see all)

  • Cutaneous Malignancies in the Organ Transplant Population - February 8, 2021
  • AHNS Basic Science/Translational Newsletter Vol 2 - April 24, 2020
Views: 0

Share:

  • Facebook
  • Twitter
  • LinkedIn

Related

Subscribe to Heads Up!

Enter your email address to subscribe to Heads Up! and receive notifications of new posts by email.

Join 204 other subscribers

AHNS Meetings

WEBINAR CALENDAR

AHNS Call For Abstracts

News and Announcements

  • AHNS 2023 Meeting – Late Breaking Call For Abstracts – Final Day To Submit Abstracts March 22, 2023
  • ARS NASBS AHNS Sinonasal Cancer Collaborative – Sinonasal Malignancy Virtual Tumor Board March 20, 2023
  • AHNS 2023 Meeting – Late Breaking Call For Abstracts – 1 Week Left To Submit Abstracts March 16, 2023
  • Registration for the AHNS 2023 is now open! March 10, 2023
  • What’s New on the AHNS Website March 9, 2023

AHNS on Facebook

AHNS on Facebook

Contact Us

AHNS, 11300 W. Olympic Blvd, Suite 600
Los Angeles, CA 90064
ph: (310) 437-0559 / fx: (310) 437-0585
[email protected]

Search this website

Follow the AHNS

  • Email
  • Facebook
  • Twitter
  • YouTube

Recent Heads Up! Posts

AHNS 2023 Meeting – Late Breaking Call For Abstracts – Final Day To Submit Abstracts

ARS NASBS AHNS Sinonasal Cancer Collaborative – Sinonasal Malignancy Virtual Tumor Board

AHNS 2023 Meeting – Late Breaking Call For Abstracts – 1 Week Left To Submit Abstracts

More News and Announcements

© 2002–2023 American Head and Neck Society · Privacy and Return Policy
· Managed by BSC Management, Inc